Description
POMALIDOMIDE ADDED TO BORTEZOMIB AND DEXAMETHASONE DELAYS DISEASE PROGRESSION IN THE SECOND-LINE TREATMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
Article: POMALIDOMIDE ADDED TO BORTEZOMIB AND DEXAMETHASONE DELAYS DISEASE PROGRESSION IN THE SECOND-LINE TREATMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Calendar of events
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart
